> ## **本文件最后更新于2021-01-29 13:47** 



-----

####  xylxp  
##### 1501#       发表于 2021-1-29 21:08



 本帖最后由 xylxp 于 2021-1-29 21:39 编辑 

强生新冠肺炎疫苗在全球临床试验中有效率为66％。


Vaccine Candidate 72% Effective in the US and 66% Effective Overall at Preventing Moderate to Severe COVID-19, 28 Days after Vaccination


85% Effective Overall in Preventing Severe Disease and Demonstrated Complete Protection Against COVID-19 related Hospitalization and Death as of Day 28


Protection Against Severe Disease Across Geographies, Ages, and Multiple Virus Variants, including the SARS-CoV-2 Variant from the B.1.351 Lineage1 Observed in South Africa


详细消息：
[https://johnsonandjohnson.gcs-we ... 0-a79e-80a39d6bda64](https://johnsonandjohnson.gcs-web.com/static-files/ad284007-6a6d-4d40-a79e-80a39d6bda64)








-----

####  d2loader  
##### 1502#       发表于 2021-1-29 21:39



<blockquote><a href="httphttps://bbs.saraba1st.com/2b/forum.php?mod=redirect&amp;goto=findpost&amp;pid=50179320&amp;ptid=1973984" target="_blank">Unlight 发表于 2021-1-29 11:04</a>

国内重组蛋白怎么样了？好像也不慢</blockquote>
智飞在乌兹别克开始三期了，最近的新闻是入组8000人左右。



希望技术路线相同没有数量级（10%）以上效果差异





                                                 